Apr 23 |
COCP: Topline Data for Influenza A and Dual Coronavirus/Norovirus Programs Expected in 2024; Model Revision Leads to Valuation of $6 Per Share…
|
Mar 28 |
Cocrystal Pharma GAAP EPS of -$1.87
|
Mar 28 |
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
|
Mar 19 |
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
|
Mar 5 |
Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap
|
Feb 20 |
COCP: Cocrystal Pharma provides updates on its clinical programs.
|
Jan 4 |
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
|
Dec 6 |
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
|
Nov 29 |
Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
|
Nov 27 |
Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023
|